SAGE Therapeutics (SAGE) Reports In-Line Q2 EPS

SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($2.13), in-line with the analyst estimate of ($2.13). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.78 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• BlockchainK2 plans private placement to raise up to $130,000